Phase 2 Eczema Trial, Recruiting NCT07298395 Sponsor: Enveda Therapeutics Condition: Eczema
Back to Eczema

Phase 2 Eczema Trial, Recruiting

NCT07298395
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with chronic atopic dermatitis (a long-term skin condition also known as eczema) for at least 12 months before the first study visit
  • People whose atopic dermatitis is rated as moderate or severe at the screening and baseline appointments, based on several standard skin assessment scores (confirm specific score thresholds with trial site)
  • People whose skin condition has not responded well to standard topical treatments (such as steroid creams), or who have not been able to tolerate those treatments, within the past 6 months
  • People who are using a plain, unfragranced moisturiser at least once a day

Who may not be able to join:

  • People with ongoing or recurring health conditions that could interfere with the study medication or the way results are measured
  • People with any illness or active infection that could affect their safety during the trial
  • People with another skin condition, or large tattoos in affected areas, that could make it difficult for doctors to properly assess their skin
  • People with a significant skin infection that requires treatment
  • People whose blood or laboratory test results show clinically significant abnormal findings at the screening appointment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Enveda Therapeutics
Registry
ClinicalTrials.gov
Start date
22 December 2025
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To evaluate the efficacy of ENV-294 compared to placebo on severity and extent of atopic dermatitis (AD)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov